Background: TIMI risk score for ST elevation myocardial infarction (STEMI) is an important tool to assess mortality risk; however, it has not yet been validated in Brazil.
Introduction
Cardiovascular diseases constitute the main cause of death in western populations, accounting for approximately 16% of all deaths in developed countries. [1] [2] [3] According to the National Registry of Myocardial Infarction (NRMI-2), 4 13.7 million North-Americans present coronary artery disease (CAD). Its prevalence increases with age, reaching 7% of individuals between 40 and 49 years of age, and 22% of those between 70 and 79.
In Brazil, in 2015, according to data from the Information Technology Department of the Public Health Care System (DATASUS), cardiovascular diseases accounted for 1,047,953 hospital admissions, of which 92,522 resulted in death by acute myocardial infarction (AMI). 5 Clinically, AMI has a strong impact on patients' quality of life and prognosis, and it is the subject of numerous clinical studies seeking new diagnostic and therapeutic strategies. Risk stratification pROCess of AMI patients has two components: early identification of patients at Original Article high risk for recurring events at the time of admission, and determination of which patients, after AMI, have a high risk of major cardiac events. Those at high risk are generally candidates for a more aggressive treatment. Individuals at a lower risk can receive conservative treatment. 6, 7 Shah et al. 8 have recently demonstrated that the use of risk scores in chest pain units may be cost-effective tools. The most well known risk stratification scores are the TIMI index, GRACE risk model, and TIMI risk score. [9] [10] [11] [12] Among them, TIMI risk score has been the most utilized in clinical practice. It was elaborated from data of 15,000 patients who were eligible for fibrinolytic therapy, and corresponds to the sum of eight variables predictors of mortality (Table 1) . 9 In Brazil, TIMI risk score is the most widely used, even though there are few studies done with our population. For that reason, and because we believe it to be a tool of easy application, we aim to validate the TIMI risk score for STEMI in our environment. We included patients who presented with chest pains and ECG showing ST-segment elevation in at least two contiguous leads, and new, or presumably new, left bundle branch block. Blood sample collection for the analysis of cardiac enzymes was done with all the patients.
Methods
Data were obtained through the data bank of one of the involved hospitals and a list of the names of all AMI patients from another hospital. TIMI risk score points were attributed as defined in Table 1 . With this information, charts were reviewed and all pertinent data were registered. A single data bank was generated. 
Statistical Analysis
The analysis was done using the software SPSS 20.0, with descriptive analysis of general data, univariate analysis through chi-square test for categorical variables, and Student's T test for continuous variables. Multivariate analysis by logistic regression was done for variables that presented p < 0.05 in the univariate analysis. Statistical significance was established at p < 0.05 for the multivariate analysis.
To estimate a sensitivity of 75%-90% with absolute error margin of 10% and confidence level of 95%, the sample had to contain at least 73 deaths, equivalent to approximately 9% of the total sample, according to the analysis by the software SPSS 22.0. In total, 811 patients were necessary. Multivariate analysis and risk score performances were based on the data of patients who had the complete necessary information for the score 
Results
A total of 34% percent of the sample was female; mean age was 59.9 +/-12.6 years. There were 602 individuals (64.2%) who were under 65 years old and were used as reference category. In regards to coronary risk factors referred at admission, 24.2% presented with diabetes mellitus type 2 (DM2); 65.8% had arterial hypertension; 36.2% had dyslipidemia; 51.8% were smokers; 22.3% presented sedentarism; and 16.7% were obese. Family history of coronary disease was found in 27.8% of the sample.
In-hospital mortality was 8.6% (81 patients).
Cardiogenic shock occurred in 10.3%, reinfarction in 3%, and stroke in 1.1%.
Reperfusion through thrombolysis was realized in 17.9% (168 patients), and through percutaneous coronary angioplasty (PTCA) in 58% (544 patients).
Rescue PTCA was done in 4.9%, and facilitated PTCA in 0.85%. Population characteristics and in-hospital mortality, by univariate analysis, are summarized in Table 2 .
Predictors of In-Hospital Mortality and Application of TIMI Score
Each clinical variable of relevance was submitted to univariate analysis, amounting to a total 22 variables (Table 2) . Age was divided into three intervals: ≥ 75 years old, between 65 and 74 years old and < 65 years old. With base on in-hospital mortality predictors of AMI, in our population, we elaborated a new risk score -the Modified TIMI score. Table 3 shows the variables that were not significant after multivariate analysis and that were excluded for the creation of a new score.
For the variables that remained significant after multivariate analysis, new scores were attributed according to the OR (Table 4) .
The score was limited between 0 and ≥ 8 points, due to the low number of individuals with higher scores (46 patients).
Graph 1
In-hospital mortality and TIMI risk score.
Graph 2 ROC curve of the TIMI score for in-hospital mortality.
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In-hospital mortality, evaluated by the new model, presented a variation between 2.3% in patients with a score of 2 points, and 47.8% for scores ≥ 8 points (Graph 3).
While assessing the AUC of the modified TIMI score, we observed a discriminatory power of 0.84 with 81% sensitivity and 75% specificity in its best index (Graph 4).
Graph 4 ROC curve of the modified TIMI score.
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Discussion
TIMI risk score for STEMI proved to be fully applicable as a robust method with a good ability to predict in-hospital mortality. In our population, composed of patients undergoing chemical and/or mechanical thrombolysis and individuals who did not receive thrombolysis, mortality of 1.4% appeared for those with a score of 2, 11.9% in patients with a score of 5, and 44.8% in patients with a score ≥ 8.
Morrow et al. applied the TIMI risk score in 84,029 patients from the 3° American Registry of AMI, which demonstrated a gradual increase of mortality as the calculated score increased. Patients with a score of 2 presented mortality within 30 days of 6.8% (not submitted to reperfusion therapy) and 2.2% (submitted to reperfusion), while those with a score of 5 had 19% mortality within 30 days (not submitted to reperfusion therapy) and 10% (with reperfusion therapy). Scores > 8 points in this population presented mortality rates of 35% in those with reperfusion therapy, and 29% without. 12 Score application in the population of the InTIME II study also showed mortality indices that were very similar to those found in our population. Of the patients with a score of 2 points, 1.3% died, while at a score of 5, mortality reached 12% in 30 days. Patients with scores > 8 points presented 32% mortality in the same period. 9 Antmann et al. evaluated the score in 20,479 patients from the Extract-TIMI 25 study, observing a mortality of 2.7% and 8.9% in patients with AMI with scores of 2 and 5 points, respectively, while those with 8 points at admission presented a 29.6% mortality. 13 The data obtained from a cohort of 2,022 patients ≥ 65 years old with AMI revealed superior mortality indices. Patients with a TIMI score of 2 points presented mortality of 4.4%, while scores ≥ 8 points showed indices of 35.6% of mortality in 30 days, though with a lower discriminatory power (0.67). 14 In the Brazilian population, Pereira et al. demonstrated a progressive increase in mortality and in the occurrence of in-hospital complications, according risk stratification by the TIMI score. 15 Results from the application of tools elaborated for risk stratification in AMI patients usually cannot be generalized. The population in which risk scores were developed invariable belong to clinical studies, and may not correspond to local reality.
Data obtained with the elaboration of the modified TIMI score show that patients with a score of 2 points had 2.3% of deaths during hospital stay, while patients with a score of 5 points presented in-hospital mortality of 12.6%. In our population, the discriminatory power of the TIMI risk score was superior to indices found in Original Article literature (0.82), and the creation of a modified TIMI score slightly increased this value (0.84). 16 The application of the score in the population of a study called Gusto I, including 41,021 patients submitted to thrombolytic therapy, demonstrated good discriminatory power (0.80). 12 Morrow et al. 12 , in turn, found different indices in patients submitted to thrombolysis (0.79), when compared to those without reperfusion (0.65), where the latter has low discriminatory power, elevating the risk of underestimating deaths. 10 When applying the score to the population from the InTime II study, the same author found good discriminatory power (0.746). When evaluating the TIMI risk score for STEMI, Antmann et al. 13 obtained similar discriminatory power (0.73).
Correia et al. 17 have recently evaluated the discriminatory power of the TIMI risk score in comparison to the GRACE risk score in 152 STEACS patients, showing a similarity between the scores, but better calibration for the TIMI risk score. 17 The comparison between the TIMI risk score and other scores (PAMI, CADILLAC, and GRACE), also done by Méndez-Eirin et al. 18 , did not show superiority for any of them, and confirmed the high accuracy of mortality prediction in all the evaluated scores. 18 Abelin et al. 19 have recently concluded that TIMI, GRACE and Zwolle scores presented adequate performance as mortality predictors in patients submitted to primary angioplasty in the current practice. Results suggest that such risk scores are the appropriate options for assessment in the real world. 19 This study presents limitations such as the fact of it being retrospective and based on previously formulated data banks; some variables were not available in all cases. Moreover, we do not have access to 30-day follow up data, and the score was validated for in-hospital mortality only.
Conclusion
TIMI risk score proved to be a fully applicable bedside tool in our population as an in-hospital mortality predictor, providing important prognostic information.
We did not find any independent variables that were not referred to in the TIMI score. The modified TIMI risk score did not show better power in the prediction of in-hospital mortality. 
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